Pfizer's early data on oral GLP-1R agonists can be effective in weight loss and blood sugar

At the American Diabetes Association (ADA) online meeting, Pfizer released a phase 1 clinical study of oral small molecule glucagon-like peptide 1 receptor (GLP-1R) in patients with type 2 diabetes (T2DM), showing that PF-06882961 showed significant results in reducing glucose levels and weightis known to be a randomized, double-blind, placebo-controlled, multiple dose-climbing phase 1 clinical study designed to explore the safety, tolerance, pharmacokinetics and pharmacodynamics of T2DM patients receiving PF-06882961 treatment for 28 daysThe study randomly divided 98 patients who were taking metformin into 8 groups (5 groups, 3 groups of alternatives), assigned a 3:1 ratio, and received PF-06882961 (twice daily, with a maximum dose of 120 mg) or placebo within 28 days, 92 of whom completed the hospitalization studyThe patient's fasting plasma glucose (FPG), 24-hour average daily glucose (MDG) and weight were assessed at baseline and 28 daysresults showed a significant reduction in FPG, MDG and weight in adult s22DM patients on the 28th dayImprovements were seen at all dose levels, but patients in the 120 mg dose group achieved the highest improvement: an average weight loss of about 18 pounds, an 89.7 mg reduction in FPG and a 105.9 mg reduction in MDG, adult patients with type 2 diabetes have multiple oral PF-06882961 and are well toleratedMost adverse events are mild, including nausea, indigestion, diarrhea, headache and constipationprevious laboratory studies of animals show that PF-06882961 (3-240mg daily) has mild to moderate damage to the heart and moderate to severe effects on the thymus (helps control infection)Giving the highest dose of the drug in rats can lead to moderate to moderate stomach ulcersPF-06882961 Molecular Structure (Source: medchemexpress.com)Pfizer highlighted the results of this experimental drug that can reduce weight in patients, the company noted: "This data provides some of the weight loss signs observed by the First Phase Study of GLP-1R agonisant PF-06882961, which can be said to be better than any GLP-1 drug that has been approved for sale."in the United States alone, type 2 diabetes affects more than 28 million people, and despite the available treatment options, many patients still have poor blood sugar controlGLP-1 agonists are a common treatment option for diabetics and can help diabetics lower blood sugar levels, including glycated hemoglobin A1c, and help reduce weight lossPF-06882961 is an oral small molecule GLP-1R agonisant that has been proven to be as effective as the injectable peptide GLP-1R agonisant in non-clinical modelsMost GLP-1 drugs are currently injectable and were introduced in 2005But it will not be approved until 2019, when Novo Nord Rybelsus (semaglutide) became the first oral GLP-1 receptor agonist available for type 2 diabetes As a result, Pfizer believes pf-06882961 could bring more welcome changes to the medication of diabetics Source: Study: Pfizer's Explorer Drug Robustly Reduces Weight and Glucose